WorldCare Clinical Expands Globally with New Offices across Europe, S. America and Asia Pacific
WorldCare Clinical, LLC
(WCC), an imaging CRO focused on maximizing the precision and accuracy of independent assessments in clinical trials, today announced new locations in Brazil, Dubai, Poland, Spain, and Singapore.
In response to sponsors’ requests to provide site support in local time zones and languages, WorldCare Clinical has expanded its technical support capabilities by working with parent company WorldCare Limited’s physicians and coordinators who offer teleradiology and second opinion services.
“Our global infrastructure has been in place for over 20 years and is essential to our business model,” commented WorldCare Limited CEO Nasser Menhall. “We are delighted to provide this service on an as-needed basis to WorldCare Clinical.”
“WorldCare Clinical is excited to expand our ability to provide 24/7 technical support to global sites by working with a pre-existing network of physicians who are already experts in managing radiology and clinical data for independent review,” said Richard Walovitch, Ph.D., president of WorldCare Clinical. “In addition to now having offices in Brazil, Dubai, Poland, Spain and Singapore, we also have access to a network of representatives in Eastern and Western Europe, the Middle East and Asia Pacific to provide advanced technical support and training as needed.”
WCC’s WorldPRO data management platform captures and consolidates all data, including images, pathology slides, pictures of skin lesions, patient feedback, and more, and organizes data for a digital central review and streamlined submission to regulatory agencies. This unique solution facilitates fast turnaround time for reviews and presents data uniformly to multi-discipline reviewers to enable the first-ever completely digital central assessment of subjective endpoints for maximum regulatory impact. For both trials that include an imaging component and those that do not, WCC can execute a blinded independent central review (BICR) of any type of clinical data.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
